Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma | Zendy

Evan Ewers | Zendy; Phalgoon A. Shah | Zendy; Mark G. Carmichael | Zendy; Tomas M. Ferguson | Zendy

Open Access

Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma

Author(s) -

Evan Ewers,

Phalgoon A. Shah,

Mark G. Carmichael,

Tomas M. Ferguson

Publication year - 2016

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofw223

Subject(s) - chemoimmunotherapy , medicine , sofosbuvir , diffuse large b cell lymphoma , virology , lymphoma , hepatitis c virus , virus , immunology , rituximab , ribavirin

Hepatitis C virus (HCV) infection is associated with the development of non-Hodgkin lymphomas. For aggressive lymphomas, such as diffuse large B-cell lymphoma (DLBCL), treatment of HCV infection is typically deferred in treatment-naive patients until after completion of lymphoma therapy [1, 2]. We report a case of HCV-associated stage IV DLBCL successfully treated concurrently using chemoimmunotherapy and a sofosbuvir-based antiviral regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research